在美国退伍军人事务医疗保健系统中发展肿瘤临床试验网络的挑战与机遇:退伍军人事务部 STARPORT 经验。

IF 2.8 4区 医学 Q2 ONCOLOGY
Abhishek A Solanki, Kevin Zheng, Alicia N Skipworth, Lisa M Robin, Ryan F Leparski, Elizabeth Henry, Matthew Rettig, Joseph K Salama, Timothy Ritter, Jeffrey Jones, Marcus Quek, Michael Chang, Alec M Block, James S Welsh, Aryavarta Kumar, Hann-Hsiang Chao, Albert C Chen, Ronald Shapiro, Rhonda L Bitting, Robert Kwon, William Stross, Lindsay Puckett, Yu-Ning Wong, Nicholas G Nickols, Kimberly Carlson
{"title":"在美国退伍军人事务医疗保健系统中发展肿瘤临床试验网络的挑战与机遇:退伍军人事务部 STARPORT 经验。","authors":"Abhishek A Solanki, Kevin Zheng, Alicia N Skipworth, Lisa M Robin, Ryan F Leparski, Elizabeth Henry, Matthew Rettig, Joseph K Salama, Timothy Ritter, Jeffrey Jones, Marcus Quek, Michael Chang, Alec M Block, James S Welsh, Aryavarta Kumar, Hann-Hsiang Chao, Albert C Chen, Ronald Shapiro, Rhonda L Bitting, Robert Kwon, William Stross, Lindsay Puckett, Yu-Ning Wong, Nicholas G Nickols, Kimberly Carlson","doi":"10.3390/curroncol31080358","DOIUrl":null,"url":null,"abstract":"<p><p>The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed a phase II/III RCT to test the use of metastasis-directed therapy in Veterans with oligometastatic prostate cancer (OMPC)-the first VA RCT in OMPC that leverages novel imaging and advanced radiotherapy techniques. To accomplish this, we developed a clinical trial network to conduct the study. In this manuscript, we describe several challenges we encountered in study development/conduct and our strategies to address them, with the goal of helping investigators establish robust study networks to conduct clinical trials. In the study start-up, we encountered challenges in timely site activation, and leveraged project management to maximize efficiency. Additionally, there were several changes in the clinical paradigms in imaging and treatment that led to protocol amendments to ensure maximum equipoise, recruitment, and impact of the study. Specifically, we amended the trial to add de novo OMPC patients (from initially only recurrent OMPC) and expanded the study to allow up to 10 metastases (from initially five). Finally, in order to maintain local study team engagement, we developed initiatives to maximize collaboration and add value to the overall clinical program through study participation.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":null,"pages":null},"PeriodicalIF":2.8000,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353739/pdf/","citationCount":"0","resultStr":"{\"title\":\"Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience.\",\"authors\":\"Abhishek A Solanki, Kevin Zheng, Alicia N Skipworth, Lisa M Robin, Ryan F Leparski, Elizabeth Henry, Matthew Rettig, Joseph K Salama, Timothy Ritter, Jeffrey Jones, Marcus Quek, Michael Chang, Alec M Block, James S Welsh, Aryavarta Kumar, Hann-Hsiang Chao, Albert C Chen, Ronald Shapiro, Rhonda L Bitting, Robert Kwon, William Stross, Lindsay Puckett, Yu-Ning Wong, Nicholas G Nickols, Kimberly Carlson\",\"doi\":\"10.3390/curroncol31080358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed a phase II/III RCT to test the use of metastasis-directed therapy in Veterans with oligometastatic prostate cancer (OMPC)-the first VA RCT in OMPC that leverages novel imaging and advanced radiotherapy techniques. To accomplish this, we developed a clinical trial network to conduct the study. In this manuscript, we describe several challenges we encountered in study development/conduct and our strategies to address them, with the goal of helping investigators establish robust study networks to conduct clinical trials. In the study start-up, we encountered challenges in timely site activation, and leveraged project management to maximize efficiency. Additionally, there were several changes in the clinical paradigms in imaging and treatment that led to protocol amendments to ensure maximum equipoise, recruitment, and impact of the study. Specifically, we amended the trial to add de novo OMPC patients (from initially only recurrent OMPC) and expanded the study to allow up to 10 metastases (from initially five). Finally, in order to maintain local study team engagement, we developed initiatives to maximize collaboration and add value to the overall clinical program through study participation.</p>\",\"PeriodicalId\":11012,\"journal\":{\"name\":\"Current oncology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-08-21\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11353739/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/curroncol31080358\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/curroncol31080358","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

美国退伍军人事务(VA)医疗保健系统在开展有影响力的肿瘤随机临床试验(RCT)方面有着悠久的历史。我们制定了一项 II/III 期 RCT,以测试转移导向疗法在寡转移性前列腺癌 (OMPC) 退伍军人中的应用情况,这是退伍军人事务部在 OMPC 领域利用新型成像和先进放疗技术开展的首项 RCT。为此,我们开发了一个临床试验网络来开展这项研究。在本手稿中,我们介绍了在研究开发/开展过程中遇到的几个挑战以及我们的应对策略,旨在帮助研究人员建立强大的研究网络来开展临床试验。在研究启动阶段,我们在及时激活研究机构方面遇到了挑战,我们利用项目管理最大限度地提高了效率。此外,由于成像和治疗方面的临床范例发生了一些变化,因此需要对方案进行修订,以确保最大限度地实现研究的平衡、招募和影响。具体来说,我们修改了试验方案,增加了新发 OMPC 患者(最初只有复发性 OMPC 患者),并扩大了研究范围,允许多达 10 例转移瘤(最初为 5 例)。最后,为了保持当地研究团队的参与度,我们制定了相关措施,以最大限度地加强合作,并通过参与研究为整个临床项目增加价值。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Challenges and Opportunities in Developing an Oncology Clinical Trial Network in the United States Veterans Affairs Health Care System: The VA STARPORT Experience.

The United States Veterans Affairs (VA) Health Care System has a strong history of conducting impactful oncology randomized clinical trials (RCTs). We developed a phase II/III RCT to test the use of metastasis-directed therapy in Veterans with oligometastatic prostate cancer (OMPC)-the first VA RCT in OMPC that leverages novel imaging and advanced radiotherapy techniques. To accomplish this, we developed a clinical trial network to conduct the study. In this manuscript, we describe several challenges we encountered in study development/conduct and our strategies to address them, with the goal of helping investigators establish robust study networks to conduct clinical trials. In the study start-up, we encountered challenges in timely site activation, and leveraged project management to maximize efficiency. Additionally, there were several changes in the clinical paradigms in imaging and treatment that led to protocol amendments to ensure maximum equipoise, recruitment, and impact of the study. Specifically, we amended the trial to add de novo OMPC patients (from initially only recurrent OMPC) and expanded the study to allow up to 10 metastases (from initially five). Finally, in order to maintain local study team engagement, we developed initiatives to maximize collaboration and add value to the overall clinical program through study participation.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current oncology
Current oncology ONCOLOGY-
CiteScore
3.30
自引率
7.70%
发文量
664
审稿时长
1 months
期刊介绍: Current Oncology is a peer-reviewed, Canadian-based and internationally respected journal. Current Oncology represents a multidisciplinary medium encompassing health care workers in the field of cancer therapy in Canada to report upon and to review progress in the management of this disease. We encourage submissions from all fields of cancer medicine, including radiation oncology, surgical oncology, medical oncology, pediatric oncology, pathology, and cancer rehabilitation and survivorship. Articles published in the journal typically contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信